BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 8167384)

  • 1. Effect of long-term treatment with a new aldose reductase inhibitor, (2S,4S)-6-fluoro-2',5'-dioxospiro-[chroman-4,4'-imidazolidine]-2-carbox amide (SNK-860), on peripheral neuropathy in streptozotocin-induced diabetic rats.
    Kato N; Mizuno K; Matsubara A; Nakano K; Kurono M; Yagihashi S
    J Diabetes Complications; 1994; 8(1):27-32. PubMed ID: 8167384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of a new aldose reductase inhibitor, (2S, 4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-ca rboxamid e (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozotocin-induced diabetic rats.
    Mizuno K; Kato N; Matsubara A; Nakano K; Kurono M
    Metabolism; 1992 Oct; 41(10):1081-6. PubMed ID: 1328819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of 15-month aldose reductase inhibition with fidarestat on the experimental diabetic neuropathy in rats.
    Kato N; Mizuno K; Makino M; Suzuki T; Yagihashi S
    Diabetes Res Clin Pract; 2000 Oct; 50(2):77-85. PubMed ID: 10960717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polyol pathway, 2,3-diphosphoglycerate in erythrocytes and diabetic neuropathy in rats.
    Nakamura J; Koh N; Sakakibara F; Hamada Y; Wakao T; Hara T; Mori K; Nakashima E; Naruse K; Hotta N
    Eur J Pharmacol; 1995 Dec; 294(1):207-14. PubMed ID: 8788433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myo-inositol or an aldose reductase inhibitor in streptozotocin-diabetic rats.
    Mayer JH; Tomlinson DR
    Diabetologia; 1983 Nov; 25(5):433-8. PubMed ID: 6197336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor Sorbinil.
    Tomlinson DR; Moriarty RJ; Mayer JH
    Diabetes; 1984 May; 33(5):470-6. PubMed ID: 6202576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of a potent new aldose reductase inhibitor, (5-(3-thienyltetrazol-1-yl)acetic acid (TAT), on diabetic neuropathy in rats.
    Hotta N; Kakuta H; Fukasawa H; Koh N; Sakakibara F; Nakamura J; Hamada Y; Wakao T; Hara T; Mori K
    Diabetes Res Clin Pract; 1995 Feb; 27(2):107-17. PubMed ID: 7607048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osmotically-induced nerve taurine depletion and the compatible osmolyte hypothesis in experimental diabetic neuropathy in the rat.
    Stevens MJ; Lattimer SA; Kamijo M; Van Huysen C; Sima AA; Greene DA
    Diabetologia; 1993 Jul; 36(7):608-14. PubMed ID: 8359577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myo-inositol and sorbitol metabolism in relation to peripheral nerve function in experimental diabetes in the rat: the effect of aldose reductase inhibition.
    Gillon KR; Hawthorne JN; Tomlinson DR
    Diabetologia; 1983 Oct; 25(4):365-71. PubMed ID: 6416913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galactosemia produces ARI-preventable nodal changes similar to those of diabetic neuropathy.
    Kamijo M; Basso M; Cherian PV; Hohman TC; Sima AA
    Diabetes Res Clin Pract; 1994 Sep; 25(2):117-29. PubMed ID: 7821191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acetyl-L-carnitine corrects the altered peripheral nerve function of experimental diabetes.
    Lowitt S; Malone JI; Salem AF; Korthals J; Benford S
    Metabolism; 1995 May; 44(5):677-80. PubMed ID: 7752919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of long-term aldose reductase inhibition on development of experimental diabetic neuropathy. Ultrastructural and morphometric studies of sural nerve in streptozocin-induced diabetic rats.
    Yagihashi S; Kamijo M; Ido Y; Mirrlees DJ
    Diabetes; 1990 Jun; 39(6):690-6. PubMed ID: 2140802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axonal transport and nerve conduction velocity in animal models of diabetic neuropathy.
    Tomlinson DR; Mayer JH
    Diabet Med; 1985 May; 2(3):210-2. PubMed ID: 2952422
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
    Shindo H; Tawata M; Aida K; Onaya T
    J Clin Endocrinol Metab; 1992 Feb; 74(2):393-8. PubMed ID: 1370506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a new aldose reductase inhibitor, 8'-chloro-2',3'-dihydrospiro [pyrrolidine-3,6'(5'H)-pyrrolo[1,2,3-de] [1,4]benzoxazine]-2,5,5'- trione (ADN-138), on delayed motor nerve conduction velocity in streptozotocin-diabetic rats.
    Hirata Y; Fujimori S; Okada K
    Metabolism; 1988 Feb; 37(2):159-63. PubMed ID: 2828821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of aldose reductase inhibition on motor nerve conduction velocity in diabetic rats.
    Yue DK; Hanwell MA; Satchell PM; Turtle JR
    Diabetes; 1982 Sep; 31(9):789-94. PubMed ID: 6819173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventive effect of long-term aldose reductase inhibition (ponalrestat) on nerve conduction and sural nerve structure in the spontaneously diabetic Bio-Breeding rat.
    Sima AA; Prashar A; Zhang WX; Chakrabarti S; Greene DA
    J Clin Invest; 1990 May; 85(5):1410-20. PubMed ID: 2110189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A combination of the aldose reductase inhibitor, statil, and the prostaglandin E1 analogue, OP1206.alpha CD, completely improves sciatic motor nerve conduction velocity in streptozocin-induced chronically diabetic rats.
    Yasuda H; Sonobe M; Hisanaga T; Kawabata T; Maeda K; Kikkawa R; Shigeta Y
    Metabolism; 1992 Jul; 41(7):778-82. PubMed ID: 1320179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of an aldose reductase inhibitor, SNK-860, on deficits in the electroretinogram of diabetic rats.
    Hotta N; Koh N; Sakakibara F; Nakamura J; Hamada Y; Naruse K; Sasaki H; Mizuno K; Matsubara A; Kakuta H
    Exp Physiol; 1995 Nov; 80(6):981-9. PubMed ID: 8962712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy.
    Mizuno K; Kato N; Makino M; Suzuki T; Shindo M
    J Diabetes Complications; 1999; 13(3):141-50. PubMed ID: 10509874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.